GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ovid Therapeutics Inc (FRA:1OT) » Definitions » Other Operating Expense

Ovid Therapeutics (FRA:1OT) Other Operating Expense : €-0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Ovid Therapeutics Other Operating Expense?

Ovid Therapeutics's Other Operating Expense for the three months ended in Jun. 2024 was €-0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.00 Mil.

Ovid Therapeutics's quarterly Other Operating Expense increased from Dec. 2023 (€-0.00 Mil) to Mar. 2024 (€0.00 Mil) but then declined from Mar. 2024 (€0.00 Mil) to Jun. 2024 (€-0.00 Mil).

Ovid Therapeutics's annual Other Operating Expense increased from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€0.00 Mil) but then declined from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).


Ovid Therapeutics Other Operating Expense Historical Data

The historical data trend for Ovid Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ovid Therapeutics Other Operating Expense Chart

Ovid Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only - - - - -

Ovid Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Ovid Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ovid Therapeutics Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Ovid Therapeutics's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Ovid Therapeutics Business Description

Traded in Other Exchanges
Address
441 Ninth Avenue, 14th Floor, New York, NY, USA, 10001
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.

Ovid Therapeutics Headlines

No Headlines